Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on 'Molecular Targets and Cancer Therapeutics' Demonstrate Superior Profile of S*BIO's Novel Anti-Cancer ...( SINGAPORE Oct. 22 /- S*BIO Pte Lt...),Health

SINGAPORE, Oct. 22 /PRNewswire/ -- S*BIO Pte Ltd today announced that multiple presentations of pre-clinical and early clinical data for its HDAC inhibitor SB939 will be made at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland. The results demonstrate that the "best-in-class" pre-clinical profile of S*BIO's novel anti-cancer drug SB939 translates into the clinic.

"We are pleased to announce clinical data from the ongoing Phase 1 trials of our orally-active HDAC inhibitor SB939," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "The pharmacokinetic and pharmacodynamic data obtained with SB939 in patients with advanced cancers are consistent with the superior HDAC inhibitor profile that we have previously demonstrated in pre-clinical studies."

"We continue to develop SB939 in the clinic to gain additional data on its anti-cancer activity as well as to demonstrate further its good tolerability and superior oral PK/PD profile."

Poster No. 136

Discovery of SB939, an HDAC inhibitor with a superior pre-clinical profile

SB939 is a potent HDAC inhibitor with superior anti-tumor efficacy and tolerability in pharmacological cancer models. The drug candidate also has favourable ADME, safety and pharmaceutical properties resulting in high and dose-proportional exposure after oral dosing. SB939 has a prolonged duration of action and is enriched in tumor tissue which may contribute to its potent anti-tumor activity and "best-in-class" profile. The structure-activity relationships leading to the discovery of SB939 will be discussed.

Poster No. 83

A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor

A robust, sensitive and quantitative Western blot assay for measuring acetylated histone 3 in tissues has been developed to evaluate the target efficacy of SB939 and is currently being used to study PK/PD relationships in the ongoing Phas
'/>"/>